Precise and Accurate CHN Data from Low Weight Samples
A new report from Exeter Analytical demonstrates how the Model 440 CHN Analyser provides precise and accurate determination of percentage carbon, hydrogen and nitrogen on samples as small as 0.3 mg.
Using Atropine (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate) as the test compound the Model 440 produced data from 0.3 mg samples which only varied within +/- 0.12% of the theoretical CHN values. In environments such as pharmaceutical research and synthetic chemistry laboratories, where the weight of new compounds for analytical purposes is often limited, the ability to reliably generate reliable CHN data on sub 0.5 milligram samples is highly valuable.
The Exeter Analytical Model 440 is a static combustion CHN Elemental Analyser, with a unique horizontal furnace design, which enables easy removal of sample residue between each analysis. Because the Model 440 is able to effectively eliminate troublesome residue build-up, its gas flow characteristics are superior to other CHN Analysers leading to longer-term calibration stability, as well as enhanced accuracy and precision for measured sample data.
Because the Model 440 provides complete control over combustion parameters it is able to reproducibly achieve 100% combustion with the widest range of sample types. Through incorporation of extensive automation in the Model 440 and intuitive software – the percentage Carbon (C), Hydrogen (H) and Nitrogen (N) in samples can be determined in as little as 5 minutes.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.